Novel nanostructured lipid-dextran sulfate hybrid carriers overcome tumor multidrug resistance of mitoxantrone hydrochloride

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 2, 2012, Pages 185-193

  Zhang, Peng ^a   Ling, Guixia ^a   Pan, Xiaolei ^a   Sun, Jin ^a   Zhang, Tianhong ^a   Pu, Xiaohui ^b   Yin, Shiliang ^a   He, Zhonggui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b HENAN UNIVERSITY   (China)

Author keywords

Cellular uptake; Mitoxantrone hydrochloride; Multidrug resistance; Nanostructured lipid dextran sulfate hybrid carriers; Pharmacokinetics

Indexed keywords

AREA UNDER THE CURVES; BIODISTRIBUTIONS; BREAST CANCER RESISTANCE PROTEINS; CANCER CELLS; CELLULAR UPTAKE; CHEMOTHERAPY AGENTS; DEXTRAN SULFATE SODIUM; ENCAPSULATION EFFICIENCY; ENDOCYTOSIS PATHWAY; IN-VIVO; INTRAVENOUS ADMINISTRATION; MITOXANTRONE; MITOXANTRONE HYDROCHLORIDE; MULTIDRUG RESISTANCE; NANO-STRUCTURED;

ANTHRACENE; CELLS; CHEMOTHERAPY; DEXTRAN; DISEASES; ENCAPSULATION; MOLECULAR BIOLOGY; PHARMACOKINETICS; SOLS; SULFUR COMPOUNDS;

SODIUM SULFATE;

BREAST CANCER RESISTANCE PROTEIN; MITOXANTRONE; NANOCARRIER; NANOSTRUCTURED LIPID DEXTRAN SULFATE HYBRID CARRIER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BRAIN; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG UPTAKE; ENCAPSULATION; ENDOCYTOSIS; HEART; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PLASMA; RAT; SPLEEN; SUSTAINED DRUG RELEASE; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL LINE, TUMOR; DEXTRAN SULFATE; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; ENDOCYTOSIS; FEMALE; HUMANS; LIPIDS; MALE; MITOXANTRONE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR;

RATTUS;

EID: 84855842755     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.06.007     Document Type: Article

References (26)

1. Stein W.D., Bates S.E., Fojo T. Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr Drug Targets 2004, 5:333-346.
2. Bolhuis H., Veen H.W., Poolman B., Driessen A.J.M., Konings W.N. Mechanism of multidrug transporters. FEMS Microbiol Rev 1997, 21:55-84.
3. Dean M., Allikmets R. Complete characterization of the human ABC gene family. J Bioenerg Biomembr 2001, 33:475-479.
4. Doughty J.C., Kane E., Cooke T.G., McArdle C.S. Mitoxantrone and methotrexate chemotherapy with and without mitomycin C in the regional treatment of locally advanced breast cancer. Breast 2002, 11:97-99.
5. Khalaf A., Pfister C., Hellot M.F., Dunet F., Moussu J., Grise P. Value of mitoxantrone in metastatic hormone-resistant prostate cancer. Prog Urol 2002, 12:37-42.
6. Hagemeister F., Cabanillas F., Coleman M., Gregory S.A., Zinzani P.L. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist 2005, 10:150-159.
7. Novoselac A.V., Reddy S., Sanmugarajah J. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone. Leukemia 2004, 18:1561-1562.
8. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998, 95:15665-15670.
9. Maliepaard M., van Gastelen M.A., de Jong L.A., Pluim D., van Waardenburg R.C., Ruevekamp-Helmers M.C., et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999, 59:4559-4563.
10. Kang K.W., Chun M.K., Kim O., Subedi R.K., Ahn S.G., Yoon J.H., et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomed Nanotechnol Biol Med 2010, 6:210-213.
11. Müller R.H., Radtke M., Wissing S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002, 242:121-128.
12. Ricci M., Puglia C., Bonina F., Di Giovanni C., Giovagnoli S., Rossi C. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC): in vitro and in vivo studies. J Pharm Sci 2005, 94:1149-1159.
13. Yuan H., Wang L.L., Du Y.Z., You J., Hu F.Q., Zeng S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B Biointerfaces 2007, 60:174-179.
14. Zhang P., Ling G., Sun J., Sun Y., Pu X., Wang Z., et al. Determination of mitoxantrone in rat plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:2260-2265.
15. Li Y., Wong H.L., Shuhendler A.J., Rauth A.M., Wu X.Y. Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. J Control Release 2008, 128:60-70.
16. Wong H.L., Rauth A.M., Bendayan R., Manias J.L., Ramaswamy M., Liu Z., et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 2006, 23:1574-1585.
17. Wong H.L., Bendayan R., Rauth A.M., Wu X.Y. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 2006, 116:275-284.
18. Yuan X., Shah B.A., Kotadia N.K., Li J., Gu H., Wu Z. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharm Res 2010, 27:1285-1295.
19. Paillard A., Passirani C., Saulnier P., Kroubi M., Garcion E., Benoît J.P., et al. Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers. Pharm Res 2010, 27:126-133.
20. Wang Y., Wang R., Lu X., Lu W., Zhang C., Liang W. Pegylated phospholipids-based self-assembly with water-soluble drugs. Pharm Res 2010, 27:361-370.
21. Ling G., Zhang P., Zhang W., Sun J., Meng X., Qin Y., et al. Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Release 2010, 148:241-248.
22. Faulds D., Balfour J.A., Chrisp P., Langtry H.D. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991, 41:400-449.
23. Schwendener R.A., Horber D.H., Rentsch K., Hänseler E., Pestalozzi B., Sauter C. Preclinical and clinical experience with liposome-encapsulated mitoxantrone. J Liposome Res 1994, 4:605-639.
24. Jain K.K. Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin Invest Drugs 2000, 9:1139-1149.
25. Wong H.L., Bendayan R., Rauth A.M., Xue H.Y., Babakhanian K., Wu X.Y. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 2006, 317:1372-1381.
26. Chen L., Li H., Zhao R., Zhu J.W. Study progress of cell endocytosis. Chin Germ J Clin Oncol 2009, 8:360-365.